Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Abstract readClinical Trial, Phase IIIRandomized Controlled TrialComparative Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.Prostate cancer and prostatic diseases · 2026Pooled it
- Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Pooled it
- Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415.International journal of radiation oncology, biology, physics · 2023Trial
- Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.Clinical and translational radiation oncology · 2026Article
- Moderately hypofractionated intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: five-year results from a single-institution study in Japan.International journal of clinical oncology · 2026Article
- Selected Blood-Accessible Biomarkers in Prostate Cancer Radiotherapy: A PRISMA-ScR Timing-Window Framework Beyond PSA.Cancers · 2026Review
- One dose of adjuvant 8 Gray postoperative radiotherapy for Merkel cell carcinoma excised with narrow margins: Low toxicity and comparable efficacy to conventional radiotherapy.Journal of the American Academy of Dermatology · 2026Article
- Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer.Clinical and translational radiation oncology · 2026Article
- Clinical outcomes of CyberKnife stereotactic radiotherapy for localized prostate cancer: comparison of 35 Gy in 5 fractions and 36 Gy in 4 fractions.Journal of radiation research · 2026Article
- Early Outcomes of Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Retrospective Analysis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Clinical Impact of PSMA PET Fusion-Based RT Planning on Dosimetry and PSA Response in Prostate Cancer.Journal of clinical medicine · 2026Article
- PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria?European journal of nuclear medicine and molecular imaging · 2026Article
- Management of high-risk prostate cancer in Spain: results from a national patterns of care survey.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Optimising Radiotherapy for Prostate Cancer: Comparison of Treatment Schedules and Toxicities.Cureus · 2026Article
- Article
- Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.Radiation oncology (London, England) · 2026Article
- The Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift.Deutsches Arzteblatt international · 2025Review
- Evaluation of Reminder App for Optimization of Bladder Filling Status During Hypo-Fractionated Irradiation for Prostate Cancer: Protocol of REFILL-PAC-HYPO Trial.Clinics and practice · 2025Article
- How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
W Robert LeeDuke University Medical Center, Durham, NC.ORCID 0000-0002-3545-0170
James J DignamDepartment of Public Health Sciences, University of Chicago, Chicago, IL.
Mahul B AminCedars-Sinai Medical Center, Los Angeles, CA.
Deborah W BrunerEmory University, Atlanta, GA.ORCID 0000-0002-5770-9948
Daniel LowUniversity of California, Los Angeles, Los Angeles, CA.
Gregory P SwansonBaylor Scott & White Healthcare Temple Clinic, Temple, TX.ORCID 0000-0002-7959-1493
Amit B ShahYork Cancer Center, York, PA.
David D'SouzaLondon Regional Cancer Program, London, ON, Canada.
Jeff M MichalskiWashington University School of Medicine, St Louis, MO.ORCID 0000-0003-0563-3766
Ian S DayesMcMaster University, Hamilton, ON, Canada.ORCID 0000-0001-8550-1485
Samantha A SeawardKaiser Permanente Northern California, Santa Clara, CA.ORCID 0000-0003-4459-4923
William A HallMedical College of Wisconsin, Milwaukee, WI.ORCID 0000-0001-7017-6755
Paul L NguyenDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Thomas M PisanskyMayo Clinic, Rochester, MN.
Sergio L FariaMcGill University Health Center, Montreal, QC, Canada.
Yuhchyau ChenUniversity of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY.
Joseph P RodgersNRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Howard M SandlerCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-8193-5769
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MRTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MRTOG Foreign AccrualsU10CA037422 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI BRUNER, DEBORAH WATKINS · 1985 to 2013
$30.4MADVANCED TECHNOLOGY QA CENTERU24CA081647 · NCI · WASHINGTON UNIVERSITY · PI MICHALSKI, JEFF M. · 1999 to 2013
$22.8MNCI NIH HHS U10 CA021661NCI NIH HHS U10 CA037422NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA081647NCI NIH HHS UG1 CA189867
Abstract
PubMed holds no abstract for this paper.
Indexed as
Dose Fractionation, RadiationProstatic NeoplasmsAgedDisease-Free SurvivalHumansMaleMiddle AgedRadiation Dose Hypofractionation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.